449 Results

People

  1. Wolchok
    Wolchok
  2. Postow
    Postow
  3. Motzer
    Motzer
  4. Callahan
    Callahan
  5. Shoushtari
    Shoushtari
  6. Allison
    Allison
  7. Panageas
    Panageas
  8. Hellmann
    Hellmann
  9. Slovin
    Slovin
  10. Chapman
    Chapman

Groups

  1. Department of Medicine (349)
  2. Solid Tumor Oncology Division (318)
  3. Melanoma and Immunotherapeutics Service (170)
  4. GSK Faculty (141)
  5. Melanoma Disease Management Team (130)
  6. Hematologic Malignancies, Division of (92)
  7. Genitourinary Oncology Service (84)
  8. Surgery (58)
  9. Weinberg Fellows (50)
  10. Sloan Kettering Institute Postdocs (43)
  1. "ipilimumab"
Formats
  1. Journal Article (349)
  2. Review (61)
  3. Editorial (17)
  4. Guidelines (5)
  5. Meeting Abstract (5)
  6. Research Letter (5)
  7. Book Section (4)
  8. Correspondence (2)
  9. Conference Paper (1)
Groups
  1. Department of Medicine (349)
  2. Solid Tumor Oncology Division (318)
  3. Melanoma and Immunotherapeutics Service (170)
  4. GSK Faculty (141)
  5. Melanoma Disease Management Team (130)
  6. Hematologic Malignancies, Division of (92)

More Groups

People
  1. Jedd Wolchok (104)
  2. Michael Postow (73)
  3. Margaret Callahan (39)
  4. Robert Motzer (31)
  5. Alexander Shoushtari (28)
  6. Paul Chapman (23)

More People

Years
  1. 2025 (21)
  2. 2024 (44)
  3. 2023 (44)
  4. 2022 (33)
  5. 2021 (26)
  6. 2020 (43)

More Years

Publications
  1. Journal of Clinical Oncology (22)
  2. Clinical Cancer Research (21)
  3. Journal for ImmunoTherapy of Cancer (20)
  4. Lancet Oncology (17)
  5. Annals of Oncology (15)
  6. European Journal of Cancer (15)

More Publications

Publishers
  1. Elsevier Inc. (65)
  2. Elsevier Science, Inc. (36)
  3. American Association for Cancer Research (31)
  4. Oxford University Press (28)
  5. American Society of Clinical Oncology (25)
  6. Wiley Blackwell (24)

More Publishers

Results (449)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials
    Journal Article

    Hauschild, A.; Ascierto, P. A.; Schadendorf, D.; Grob, J. J.; Ribas, A.; Kiecker, F.; Dutriaux, C.; Demidov, L. V.; Lebbé, C.; Rutkowski, P.; more...
    European Journal of Cancer (2020)

    Fulltext@MSK | Save
  • P2RY8-CRLF2 fusion–positive acute myeloid leukemia with myelodysplasia-related changes: Response to novel therapy
    Journal Article

    Aypar, U.; Taylor, J.; Garcia, J. S.; Momeni-Boroujeni, A.; Gao, Q.; Baik, J.; Londono, D.; Benayed, R.; Sigler, A.; Haddadin, M.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • Treatment-free survival: A novel outcome measure of the effects of immune checkpoint inhibition - A pooled analysis of patients with advanced melanoma
    Journal Article

    Regan, M. M.; Werner, L.; Rao, S.; Gupte-Singh, K.; Hodi, F. S.; Kirkwood, J. M.; Kluger, H. M.; Larkin, J.; Postow, M. A.; Ritchings, C.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A multicenter, open-label, exploratory platform study to evaluate biomarkers and immunotherapy combinations for the treatment of patients with metastatic castration-resistant prostate cancer (PORTER)
    Meeting Abstract

    Nissola, L.; Autio, K.; Bhardwaj, N.; Galsky, M.; Wentzel, K.; Lucey, V.; Selinsky, C.; Perry, C.; Cabanski, C.; Bitton, A.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • When should we irradiate the primary in metastatic lung cancer?
    Review

    Shiarli, A. M.; McDonald, F.; Gomez, D. R.
    Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
    Journal Article

    Wei, S. C.; Anang, N. A. A. S.; Sharma, R.; Andrews, M. C.; Reuben, A.; Levine, J. H.; Cogdill, A. P.; Mancuso, J. J.; Wargo, J. A.; Pe’er, D.; more...
    Proceedings of the National Academy of Sciences of the United States of America (2019)

    Fulltext@MSK | Save
  • Dermatologic toxicities: Rash, mucosal irritation, and pruritus
    Book Section

    Wu, J.; Lacouture, M. E.
    In Ernstoff, M. S.; Puzanov, I.; Robert, C.; Diab, A.; Hersey, P. (Eds.) SITC's Guide to Managing Immunotherapy Toxicity (2019)

    Fulltext@MSK | Save
  • New lung cancer treatments (immunotherapy and targeted therapies) and their associations with depression and other psychological side effects as compared to chemotherapy
    Journal Article

    McFarland, D. C.
    General Hospital Psychiatry (2019)

    Fulltext@MSK | Save
  • Indirect treatment comparison of nivolumab versus observation or ipilimumab as adjuvant therapy in resected melanoma using pooled clinical trial data
    Journal Article

    Freeman, M.; Betts, K. A.; Jiang, S.; Du, E. X.; Gupte-Singh, K.; Lu, Y.; Rao, S.; Shoushtari, A. N.
    Advances in Therapy (2019)

    Fulltext@MSK | Save
  • Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: Extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
    Journal Article

    Motzer, R. J.; Rini, B. I.; McDermott, D. F.; Arén Frontera, O.; Hammers, H. J.; Carducci, M. A.; Salman, P.; Escudier, B.; Beuselinck, B.; Amin, A.; more...
    Lancet Oncology (2019)

    Fulltext@MSK | Save